Inflammatory Myopathy clinical trials

Explore recruiting inflammatory myopathy clinical trials.

Recruiting inflammatory myopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Inflammatory Myopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy

Italy, Spain, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

C0251010 - A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)

Bulgaria, Hungary, Sweden, Italy, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy

Slovakia, Spain, Czechia, Italy, Belgium, Netherlands +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myopathies

Hungary, Poland, Czechia, Italy, Germany, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Inflammatory Myopathy trials by city

Inflammatory Myopathy in Toronto Inflammatory Myopathy in Vancouver Inflammatory Myopathy in Montreal Inflammatory Myopathy in Calgary Inflammatory Myopathy in Edmonton Inflammatory Myopathy in Ottawa Inflammatory Myopathy in Winnipeg Inflammatory Myopathy in Quebec City Inflammatory Myopathy in Hamilton Inflammatory Myopathy in Kitchener Inflammatory Myopathy in London Inflammatory Myopathy in Halifax Inflammatory Myopathy in New York Inflammatory Myopathy in Los Angeles Inflammatory Myopathy in Chicago Inflammatory Myopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease